载药纳米粒控释地塞米松磷酸钠抑制实验性角膜新生血管。
Controlled release of dexamethasone sodium phosphate with biodegradable nanoparticles for preventing experimental corneal neovascularization.
机构信息
Department of Ophthalmology, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, PR China; Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Center for Nanomedicine, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Center for Nanomedicine, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai, PR China.
出版信息
Nanomedicine. 2019 Apr;17:119-123. doi: 10.1016/j.nano.2019.01.001. Epub 2019 Jan 21.
Corneal neovascularization (CNV) leads to the loss of corneal transparency and vision impairment, and can ultimately cause blindness. Topical corticosteroids are the first line treatment for suppressing CNV, but poor ocular bioavailability and rapid clearance of eye drops makes frequent administration necessary. Patient compliance with frequent eye drop application regimens is poor. We developed biodegradable nanoparticles (NP) loaded with dexamethasone sodium phosphate (DSP) using zinc ion bridging, DSP-Zn-NP, with dense coatings of poly(ethylene glycol) (PEG). DSP-Zn-NP were safe and capable of providing sustained delivery of DSP to the front of the eye following subconjunctival (SCT) administration in rats. We reported that a single SCT administration of DSP-Zn-NP prevented suture-induced CNV in rats for two weeks. In contrast, the eyes receiving SCT administration of either saline or DSP solution developed extensive CNV in less than 1 week. SCT administration of DSP-Zn-NP could be an effective strategy in preventing and treating CNV.
角膜新生血管（CNV）可导致角膜透明度丧失和视力损害，最终可导致失明。局部皮质类固醇是抑制 CNV 的一线治疗方法，但眼部生物利用度差和滴眼液清除迅速，需要频繁给药。患者对频繁滴眼方案的依从性较差。我们使用锌离子桥接开发了负载磷酸二氢钠地塞米松（DSP）的可生物降解纳米颗粒（NP），即 DSP-Zn-NP，其表面覆盖有密集的聚乙二醇（PEG）。DSP-Zn-NP 安全，并且能够在大鼠结膜下（SCT）给药后向眼前部持续递送 DSP。我们报道，单次 SCT 给予 DSP-Zn-NP 可预防大鼠缝线诱导的 CNV 达两周。相比之下，接受 SCT 生理盐水或 DSP 溶液给药的眼睛在不到 1 周内就发生了广泛的 CNV。SCT 给予 DSP-Zn-NP 可能是预防和治疗 CNV 的有效策略。
Zotero 插件